A fresh look at covalent BTK inhibitor resistance.
作者信息
Roeker Lindsey E
机构信息
Memorial Sloan Kettering Cancer Center.
出版信息
Blood. 2024 Sep 5;144(10):1029-1031. doi: 10.1182/blood.2024025237.
Abstract
摘要
相似文献
1
A fresh look at covalent BTK inhibitor resistance.重新审视共价布鲁顿酪氨酸激酶（BTK）抑制剂耐药性。
Blood. 2024 Sep 5;144(10):1029-1031. doi: 10.1182/blood.2024025237.
2
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.华氏巨球蛋白血症中的第一代和第二代布鲁顿酪氨酸激酶抑制剂
Hematol Oncol Clin North Am. 2018 Oct;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012. Epub 2018 Jul 19.
3
Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.具有额外三打击基因型的转化型套细胞淋巴瘤可能对布鲁顿酪氨酸激酶抑制剂耐药。
Blood. 2024 May 16;143(20):2106. doi: 10.1182/blood.2024023818.
4
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.布鲁顿酪氨酸激酶抑制增加慢性淋巴细胞白血病对BCL-2的依赖性并增强对维奈托克的敏感性。
Leukemia. 2017 Oct;31(10):2075-2084. doi: 10.1038/leu.2017.32. Epub 2017 Jan 23.
5
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.布鲁顿酪氨酸激酶（BTK）A428D 突变导致慢性淋巴细胞白血病对 BTK 降解剂治疗产生耐药性。
Leukemia. 2024 Aug;38(8):1818-1821. doi: 10.1038/s41375-024-02317-4. Epub 2024 Jul 24.
6
Second-generation inhibitors of Bruton tyrosine kinase.布鲁顿酪氨酸激酶第二代抑制剂
J Hematol Oncol. 2016 Sep 2;9(1):80. doi: 10.1186/s13045-016-0313-y.
7
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk mutation in B-cell malignancies.一种非共价抑制剂 XMU-MP-3 克服了 B 细胞恶性肿瘤中伊布替尼耐药的 Btk 突变。
Br J Pharmacol. 2019 Dec;176(23):4491-4509. doi: 10.1111/bph.14809. Epub 2019 Dec 9.
8
An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.评价泽布替尼，一种 BTK 抑制剂，用于治疗慢性淋巴细胞白血病。
Expert Rev Hematol. 2020 Oct;13(10):1039-1046. doi: 10.1080/17474086.2020.1817735. Epub 2020 Sep 14.
9
Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.泊鲁替尼：首个用于治疗成人复发/难治性套细胞淋巴瘤的非共价酪氨酸激酶抑制剂。
Curr Med Chem. 2024;31(30):4757-4762. doi: 10.2174/0109298673251030231004052822.
10
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors.慢性淋巴细胞白血病中的新型耐药机制：第二代及非共价布鲁顿酪氨酸激酶（BTK）抑制剂中的BTK变异突变
Blood. 2025 Mar 6;145(10):1005-1009. doi: 10.1182/blood.2024026672.
引用本文的文献
1
Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation.慢性淋巴细胞白血病：正在研究的新型治疗靶点
Cancers (Basel). 2025 Jul 10;17(14):2298. doi: 10.3390/cancers17142298.
2
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies.用于B细胞恶性肿瘤的布鲁顿酪氨酸激酶（BTK）抑制剂及下一代BTK靶向疗法。
Arch Pharm Res. 2025 May 8. doi: 10.1007/s12272-025-01546-0.
3
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.多重数字PCR能够灵敏地检测对布鲁顿酪氨酸激酶（BTK）抑制剂的耐药性。
Ann Hematol. 2025 May;104(5):2889-2895. doi: 10.1007/s00277-025-06200-9. Epub 2025 Jan 24.
本文引用的文献
1
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.在接受阿卡替尼或伊布替尼治疗的慢性淋巴细胞白血病进展的患者中，突变特征。
Blood. 2024 Sep 5;144(10):1061-1068. doi: 10.1182/blood.2023023659.
2
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.激酶结构域缺失的 BTK 突变易受临床阶段 BTK 和 IKZF1/3 降解剂 NX-2127 的影响。
Science. 2024 Feb 2;383(6682):eadi5798. doi: 10.1126/science.adi5798.
3
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.在慢性淋巴细胞白血病中使用共价 BTK 抑制剂后使用 pirtobrutinib。
N Engl J Med. 2023 Jul 6;389(1):33-44. doi: 10.1056/NEJMoa2300696.
4
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.非共价布鲁顿酪氨酸激酶抑制剂耐药机制。
N Engl J Med. 2022 Feb 24;386(8):735-743. doi: 10.1056/NEJMoa2114110.
5
BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶介导的慢性淋巴细胞白血病对依鲁替尼的耐药性
J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.
6
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.导致慢性淋巴细胞白血病对伊布替尼耐药的克隆进化。
Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.
7
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.伊布替尼的布鲁顿酪氨酸激酶抑制剂耐药机制。
N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.
Zotero 插件